Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Review, H1 2015

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Review, H1 2015', provides an overview of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)'s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Overview 8

Therapeutics Development 9

Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Overview 9

Pipeline Products for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Comparative Analysis 10

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Therapeutics under Development by Companies 11

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline Products Glance 12

Late Stage Products 12

Clinical Stage Products 13

Early Stage Products 14

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Products under Development by Companies 15

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Companies Involved in Therapeutics Development 16

Anthera Pharmaceuticals Inc. 16

Azano Pharmaceuticals Inc. 17

Boehringer Ingelheim GmbH 18

Bristol-Myers Squibb Company 19

Eisai Co., Ltd. 20

GlaxoSmithKline plc 21

HanAll Biopharma Co., Ltd. 22

Immunomedics, Inc. 23

Merck & Co., Inc. 24

Momenta Pharmaceuticals, Inc. 25

Pfizer Inc. 26

PhytoHealth Corporation 27

Rigel Pharmaceuticals, Inc. 28

SuppreMol GmbH 29

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Therapeutics Assessment 30

Assessment by Monotherapy Products 30

Assessment by Target 31

Assessment by Mechanism of Action 33

Assessment by Route of Administration 35

Assessment by Molecule Type 37

Drug Profiles 39

Antibody for Autoimmune Disorders and Inflammation-Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

avatrombopag-Drug Profile 40

Product Description 40

Mechanism of Action 40

R&D Progress 40

AZ-175-Drug Profile 41

Product Description 41

Mechanism of Action 41

R&D Progress 41

belimumab-Drug Profile 42

Product Description 42

Mechanism of Action 42

R&D Progress 42

BI-655064-Drug Profile 45

Product Description 45

Mechanism of Action 45

R&D Progress 45

blisibimod-Drug Profile 46

Product Description 46

Mechanism of Action 46

R&D Progress 46

BMS-986004-Drug Profile 49

Product Description 49

Mechanism of Action 49

R&D Progress 49

eltrombopag olamine-Drug Profile 50

Product Description 50

Mechanism of Action 50

R&D Progress 50

fostamatinib disodium-Drug Profile 53

Product Description 53

Mechanism of Action 53

R&D Progress 53

GL-2045-Drug Profile 56

Product Description 56

Mechanism of Action 56

R&D Progress 56

GSK-2285921-Drug Profile 57

Product Description 57

Mechanism of Action 57

R&D Progress 57

HL-161-Drug Profile 59

Product Description 59

Mechanism of Action 59

R&D Progress 59

MK-8723-Drug Profile 60

Product Description 60

Mechanism of Action 60

R&D Progress 60

PHN-013-Drug Profile 61

Product Description 61

Mechanism of Action 61

R&D Progress 61

SM-101-Drug Profile 62

Product Description 62

Mechanism of Action 62

R&D Progress 62

veltuzumab-Drug Profile 64

Product Description 64

Mechanism of Action 64

R&D Progress 64

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Recent Pipeline Updates 67

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Dormant Projects 81

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Discontinued Products 82

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Product Development Milestones 83

Featured News & Press Releases 83

Feb 06, 2015: GSK announces EU regulatory submission seeking additional indication for eltrombopag (Revolade) 83

Dec 22, 2014: GSK announces US regulatory submission seeking additional indication for eltrombopag (Promacta) 83

Jul 16, 2014: Rigel Initiates Phase 3 Studies of Fostamatinib in ITP 83

Dec 09, 2013: Immunomedics Reports Promising Activity With Veltuzumab In Relapsed Immune Thrombocytopenia 84

Oct 24, 2013: Rigel Provides Update On Oral SYK Inhibitor Fostamatinib 85

Jul 24, 2013: NICE says yes to blood disorder treatment in final guidance 85

Jun 12, 2013: GSK's Revolade Receives Positive Recommendation From NICE For Treatment Of Idiopathic Thrombocytopenic Purpura 86

Mar 20, 2013: GSK's Eltrombopag Receives NICE Recommendation For Treatment Of Chronic Immune Thrombocytopenic Purpura 86

Dec 18, 2012: NICE Recommends GlaxoSmithKline's Eltrombopag For Treatment Of Chronic Immune Thrombocytopenic Purpura 87

Dec 11, 2012: Immunomedics Provides Clinical Updates On Subcutaneous Injections Of Veltuzumab In Autoimmune Disease And Cancer 88

Appendix 90

Methodology 90

Coverage 90

Secondary Research 90

Primary Research 90

Expert Panel Validation 90

Contact Us 90

Disclaimer 91

List of Tables

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H1 2015 9

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Comparative Analysis by Early Stage Development, H1 2015 14

Products under Development by Companies, H1 2015 15

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Anthera Pharmaceuticals Inc., H1 2015 16

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Azano Pharmaceuticals Inc., H1 2015 17

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Boehringer Ingelheim GmbH, H1 2015 18

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Bristol-Myers Squibb Company, H1 2015 19

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Eisai Co., Ltd., H1 2015 20

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by GlaxoSmithKline plc, H1 2015 21

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by HanAll Biopharma Co., Ltd., H1 2015 22

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Immunomedics, Inc., H1 2015 23

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Merck & Co., Inc., H1 2015 24

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Momenta Pharmaceuticals, Inc., H1 2015 25

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Pfizer Inc., H1 2015 26

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by PhytoHealth Corporation, H1 2015 27

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by Rigel Pharmaceuticals, Inc., H1 2015 28

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Pipeline by SuppreMol GmbH, H1 2015 29

Assessment by Monotherapy Products, H1 2015 30

Number of Products by Stage and Target, H1 2015 32

Number of Products by Stage and Mechanism of Action, H1 2015 34

Number of Products by Stage and Route of Administration, H1 2015 36

Number of Products by Stage and Molecule Type, H1 2015 38

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics-Recent Pipeline Updates, H1 2015 67

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Dormant Projects, H1 2015 81

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Discontinued Products, H1 2015 82

List of Figures

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura), H1 2015 9

Number of Products under Development for Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura)-Comparative Analysis, H1 2015 10

Number of Products under Development by Companies, H1 2015 11

Comparative Analysis by Late Stage Development, H1 2015 12

Comparative Analysis by Clinical Stage Development, H1 2015 13

Assessment by Monotherapy Products, H1 2015 30

Number of Products by Top 10 Targets, H1 2015 31

Number of Products by Stage and Top 10 Targets, H1 2015 32

Number of Products by Top 10 Mechanism of Actions, H1 2015 33

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 34

Number of Products by Top 10 Routes of Administration, H1 2015 35

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 36

Number of Products by Top 10 Molecule Types, H1 2015 37

Number of Products by Stage and Top 10 Molecule Types, H1 2015 38

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Anthera Pharmaceuticals Inc.

Azano Pharmaceuticals Inc.

Boehringer Ingelheim GmbH

Bristol-Myers Squibb Company

Eisai Co., Ltd.

GlaxoSmithKline plc

HanAll Biopharma Co., Ltd.

Immunomedics, Inc.

Merck & Co., Inc.

Momenta Pharmaceuticals, Inc.

Pfizer Inc.

PhytoHealth Corporation

Rigel Pharmaceuticals, Inc.

SuppreMol GmbH

Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutic Products under Development, Key Players in Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Therapeutics, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Pipeline Overview, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Pipeline, Idiopathic Thrombocytopenic Purpura (Immune Thrombocytopenic Purpura) Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com